Cloning Concerns
By Richard Hayes,
Washington Post
| 11. 24. 2007
As the Nov. 21 front-page article "Advance May End Stem Cell Debate" implied, religious conservatives are not the only ones concerned about the use of human cloning for stem cell research. Many liberals, progressives and supporters of women's health and reproductive rights are uneasy for reasons of their own.
Cloning-based stem cell therapies have been projected to cost upward of $100,000 per treatment, raising questions of health equity and access.
Cloning for stem cell research opens the door to reproductive cloning and to high-tech eugenic and "designer baby" applications. And millions of women's eggs would be needed each year to supply the proposed cloning-based "personalized medicine" industry.
With this week's stem cell breakthroughs, the embryo wars may be behind us. Liberals are now in a position to take the lead in drawing attention to the social justice and human rights concerns that the new human genetic technologies raise.
RICHARD HAYES
Executive Director
Center for Genetics and Society
Oakland, Calif.
Related Articles
By Tomoko Otake, The Japan Times | 04.09.2024
A decade ago, researcher Haruko Obokata caused a sensation when she published two papers in the journal Nature, in which she claimed that she had discovered a way to create stem cells easily using the so-called STAP method.
With STAP...
By Ian Sample, The Guardian | 03.08.2024
Scientists are a step closer to making IVF eggs from patients’ skin cells after adapting the procedure that created Dolly the sheep, the first cloned mammal, more than two decades ago.
The work raises the prospect of older women being...
By Ramon Antonio Vargas, The Guardian | 02.28.2024
Doctors say a man in California who contracted blood cancer while living with HIV is in remission from both potentially fatal illnesses thanks to a treatment they are hailing as remarkable and encouraging.
Paul Edmonds is only the fifth-known person...
By Victoria Gray, Uduak Thomas, and Kevin Davies, The CRISPR Journal | 02.14.2024
In July 2019, medical staff in Nashville dosed the first U.S. patient in the exa-cel therapy trial, sponsored by Vertex Pharmaceuticals and CRISPR Therapeutics. That first patient was Victoria Gray, a mother of four from Forest, Mississippi, a sickle cell...
